XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net sales $ 551,519 $ 500,051
Cost of goods sold 249,316 229,988
Gross profit 302,203 270,063
Selling, general and administrative expense 209,130 194,402
Research and Development Expense 49,427 49,452
Segment profit (loss) 43,646 26,209
Interest expense 5,782 5,316
Foreign exchange losses, net 1,254 1,789
Unrealized Gain (Loss) on Securities (815,934) 0
Nonoperating Income (Expense) 11,145 1,043
Income before income taxes 863,689 20,147
Provision for income taxes (206,915) (7,734)
Net income attributable to Bio-Rad $ 656,774 $ 12,413
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 22.05 $ 0.42
Weighted average common shares - basic 29,787 29,580
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 21.77 $ 0.41
Weighted average common shares - diluted 30,171 29,911